Eli Lilly CEO says company can help 'respond' to national security concerns around essential drugs as tariffs loom
1. Eli Lilly's CEO warns of pharmaceutical tariffs affecting drug supply chains. 2. Generic drugs, crucial for hospitals, might face production disruptions. 3. Eli Lilly plans to invest $27 billion in U.S. manufacturing expansion. 4. CEO Ricks questions the necessity of tariffs amid reshoring efforts. 5. Lower tax rates for domestic production could attract pharmaceutical manufacturers.